In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
1. Executive Summary During April 2026, MARA issued 12 rating actions across multiple therapeutic areas. The monthly distribution was concentrated in B+ (Very Weak) and B++ (Marginal), with no A-range,
Executive Summary MARA is currently finalizing a series of reimbursement risk assessments across twelve drug–indication pairs spanning oncology, rare diseases, immunology, nephrology, and cardiovascular conditions. These assessments have been initiated
Link to the latest MARA Rating Executive SummaryThe MARA Rating for Leqembi (lecanemab) in early Alzheimer’s disease has been affirmed at B++ (Marginal) as of March 2026 following structured committee review. The rating band
Link to the full report here 1. Executive Summary MARA Rating has completed a formal surveillance review of CagriSema (cagrilintide + semaglutide) following publication of Phase 3 head-to-head results versus
Executive Summary In February 2026, MARA published 37 rating actions. The month was notable not only for volume, but for compression of the rating profile into the lower-middle bands. One
Executive Summary In January 2026, MARA issued nine initial reimbursement risk assessments across cardiology, infectious disease, neurology, oncology, obesity, and immunology. The monthly profile was concentrated in the middle of
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split:
How Evidence Quality Scores Impact HTA Assessment Success: The 2.9 Benchmark Since 2020, assets with an average Evidence Quality score of 2.9 have sailed through HTA assessments more regularly than
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system